The stochastic equations are: Exp(-2 684 to 0 1296*LN(age)) for men;
Exp(-2 676 to 0.2357*LN(age)) for women.
characterised by a significant proportion of infections occurring during the perinatal period, of which more than 50% remain chronic carriers of the virus; the other is characterised by early childhood (horizontal) transmission of infection. (Fig 1) . Another longterm follow up study showed that 13%, 27%, and 42% of 1236 liver cirrhosis patients developed hepatocellular carcinoma within five, 10, and 15 years, respectively. The progression rate to hepatocellular carcinoma among HBsAg positive liver cirrhosis patients was also significantly higher than that among HBsAg negative patients with liver cirrhosis (Fig 2) .
Importantly, authors of a large scale cohort study carried out in Seoul, Korea observed a protective effect of hepatitis B vaccination against development of hepatocellular carcinoma in adult men (Table VII) .16 They also reported a 16.4:1 risk ratio for hepatocellular carcinoma among HBsAg positive subjects compared with those who were negative for both HBsAg and anti-HBs. The risk among anti-HBs positive subjects is reduced even further, to 033. Four year follow up after hepatitis B vaccination also showed that the incidence of hepatocellular carcinoma among vaccinees is lower than that among nonvaccinees (with a ratio of 0-58:1, respectively).
Hepatitis B vaccination strategy/programme There are several issues to be considered when hepatitis B vaccination programmes are being developed. As previously mentioned, the vaccination strategy/programme will vary from one country to another and from one type of region (urban) to another (rural), depending on the epidemiological characteristics of HBV infection and its consequences. 
